GLOBAL PIVOTAL PHASE 2 TRIAL OF THE CD19‐TARGETED THERAPY CTL019 IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY (R/R) DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL)—AN INTERIM ANALYSIS. (June 2017) - Schuster, S.J.